Hormonal
GLP-1 receptor agonists provide superior clinical outcomes compared to insulin in type 2 diabetes, offering better glycemic control, significant weight loss, and reduced hypoglycemia risk.
For type 2 diabetics struggling with oral meds, switching to a GLP-1 receptor agonist (like semaglutide or dulaglutide) is clinically superior to starting insulin. You will likely lose weight, have lower blood pressure, and avoid dangerous low-blood-sugar episodes, while achieving better or equal blood sugar control. These drugs are easier to use (up to once weekly) and do not require the complex titration of insulin.
Compared to insulin, GLP-1 RAs reduced HbA1c more effectively (Δ - 0.17 %, p < 0.0001)... GLP-1 RAs reduced body weight more effectively (Δ - 3.71 kg; p < 0.0001). The proportion of patients experiencing hypoglycaemic episodes was 34 % lower with GLP-1 RAs (p < 0.0001)... Slightly better glycaemic control can be achieved by adding GLP-1 RAs to OGLM as compared to insulin treatment, with added benefits regarding body weight, hypoglycaemia, blood pressure and lipoproteins.
Why this rating
Meta-analysis of 19 randomized head-to-head trials (n=8854).
Source
A meta‐analysis comparing clinical effects of short‐ or long‐acting <scp>GLP</scp> ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
Mirna S. Abd El Aziz et al. · Diabetes Obesity and Metabolism · 2016
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →